TransCode Therapeutics Retains Tungsten Advisors for Strategic Review
TransCode Therapeutics has engaged Tungsten Advisors to lead a formal strategic process aimed at maximizing the value of its lead therapeutic candidate, TTX-MC138, and its broader oncology portfolio.